Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab

被引：52

作者：

von Bonin, Malte ^{[1
]}

Oelschlaegel, Uta ^{[1
]}

Radke, Joergen ^{[1
]}

Stewart, Michelle ^{[1
]}

Ehninger, Gerhard ^{[1
]}

Bornhauser, Martin ^{[1
]}

Platzbecker, Uwe ^{[1
]}

机构：

[1] Univ Hosp Carl Gustav Carus, Med Klin & Poliklin 1, D-01307 Dresden, Germany

来源：

TRANSPLANTATION | 2008年 / 86卷 / 06期

关键词：

allogeneic hematopoetic stem-cell transplantation; chronic graft-versus-host disease; low-dose rituximab;

D O I：

10.1097/TP.0b013e318183f662

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Rituximab, an anti-CD20 chimeric monoclonal antibody, is widely used in hematologic malignancies and has been introduced as a therapeutic option in autoimmune disorders. In recent studies, rituximab has shown promising activity in steroid-refractory chronic graft-versus-host disease (cGvHD) at a weekly dose of 375 mg/m(2). We now report on 13 Subjects after peripheral blood stem-cell transplantation receiving low-close rituximab (50 mg/m(2)) for steroid-refractory cGvHD and autoimmune disorders (membranous glomerulonephritis and immune thrombocytopenic purpura). The overall response rate was 69%, including two patients with complete responses. In accordance, we observed clearance of periperal blood B cells even after the first dose of rituximab in four patients. We Conclude that low-dose rituximab seems to be active and safe in intensively pretreated patients with steroid-refractory cGvHD.

引用

页码：875 / 879

页数：5